相似文献
1
Oncolytic viruses: now interviewing for the all-star game.
Mol Ther. 2010 May;18(5):866-8. doi: 10.1038/mt.2010.60.
2
Development of Group B Coxsackievirus as an Oncolytic Virus: Opportunities and Challenges.
Viruses. 2021 Jun 5;13(6):1082. doi: 10.3390/v13061082.
3
Introduction to Oncolytic Virotherapy.
Methods Mol Biol. 2020;2058:1-6. doi: 10.1007/978-1-4939-9794-7_1.
4
Oncolytic virus therapy: A new era of cancer treatment at dawn.
Cancer Sci. 2016 Oct;107(10):1373-1379. doi: 10.1111/cas.13027. Epub 2016 Sep 9.
5
Biosafety of non-human therapeutic viruses in clinical gene therapy.
Curr Gene Ther. 2013 Dec;13(6):492-9. doi: 10.2174/156652321306140103224907.
6
A Phase 1 Trial of Oncolytic Adenovirus ICOVIR-5 Administered Intravenously to Cutaneous and Uveal Melanoma Patients.
Hum Gene Ther. 2019 Mar;30(3):352-364. doi: 10.1089/hum.2018.107. Epub 2018 Nov 13.
7
The role of talimogene laherparepvec (T-VEC) in the age of checkpoint inhibitors.
Clin Adv Hematol Oncol. 2016 Aug;14(8):576-9.
8
Oncolytic Viro-Immunotherapy: An Emerging Option in the Treatment of Gliomas.
Front Immunol. 2021 Oct 5;12:721830. doi: 10.3389/fimmu.2021.721830. eCollection 2021.
9
Advance in herpes simplex viruses for cancer therapy.
Sci China Life Sci. 2013 Apr;56(4):298-305. doi: 10.1007/s11427-013-4466-4. Epub 2013 Apr 7.
10
Targeted Metabolic Reprogramming to Improve the Efficacy of Oncolytic Virus Therapy.
Mol Ther. 2020 Jun 3;28(6):1417-1421. doi: 10.1016/j.ymthe.2020.03.014. Epub 2020 Mar 20.
本文引用的文献
1
Synergistic interaction between oncolytic viruses augments tumor killing.
Mol Ther. 2010 May;18(5):888-95. doi: 10.1038/mt.2010.44. Epub 2010 Mar 16.
2
Modulation of innate immune signalling pathways by viral proteins.
Adv Exp Med Biol. 2009;666:49-63. doi: 10.1007/978-1-4419-1601-3_4.
3
The interferon system and vaccinia virus evasion mechanisms.
J Interferon Cytokine Res. 2009 Sep;29(9):581-98. doi: 10.1089/jir.2009.0073.
4
Oncolytic viruses: time to compare, contrast, and combine? 5th international meeting on replicating oncolytic virus therapeutics. Banff, Alberta, Canada, 18-22 March 2009.
Mol Ther. 2009 Jun;17(6):934-5. doi: 10.1038/mt.2009.86.
5
The p14 FAST protein of reptilian reovirus increases vesicular stomatitis virus neuropathogenesis.
J Virol. 2009 Jan;83(2):552-61. doi: 10.1128/JVI.01921-08. Epub 2008 Oct 29.
6
Reprogrammed viruses as cancer therapeutics: targeted, armed and shielded.
Nat Rev Microbiol. 2008 Jul;6(7):529-40. doi: 10.1038/nrmicro1927.
7
VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents.
Cancer Cell. 2003 Oct;4(4):263-75. doi: 10.1016/s1535-6108(03)00241-1.
8
Development of a replication-selective, oncolytic poxvirus for the treatment of human cancers.
Cancer Gene Ther. 2002 Dec;9(12):1001-12. doi: 10.1038/sj.cgt.7700549.
9
Systemic cancer therapy with a tumor-selective vaccinia virus mutant lacking thymidine kinase and vaccinia growth factor genes.
Cancer Res. 2001 Dec 15;61(24):8751-7.
10
Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus.
Nat Med. 2000 Jul;6(7):821-5. doi: 10.1038/77558.
Zotero 插件